HomeCompareABIO vs EPRT

ABIO vs EPRT: Dividend Comparison 2026

ABIO yields 11.04% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $21.9K in total portfolio value· pulled ahead in Year 7
10 years
ABIO
ABIO
● Live price
11.04%
Share price
$28.80
Annual div
$3.18
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.5K
Annual income
$2,204.34
Full ABIO calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ABIO vs EPRT

📍 EPRT pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABIOEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABIO + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABIO pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABIO
Annual income on $10K today (after 15% tax)
$938.54/yr
After 10yr DRIP, annual income (after tax)
$1,873.69/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,040.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABIO + EPRT for your $10,000?

ABIO: 50%EPRT: 50%
100% EPRT50/50100% ABIO
Portfolio after 10yr
$52.4K
Annual income
$7,522.53/yr
Blended yield
14.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ABIO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.7
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABIO buys
0
EPRT buys
0
No recent congressional trades found for ABIO or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABIOEPRT
Forward yield11.04%3.92%
Annual dividend / share$3.18$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$41.5K$63.4K
Annual income after 10y$2,204.34$12,840.73
Total dividends collected$16.5K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ABIO vs EPRT ($10,000, DRIP)

YearABIO PortfolioABIO Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,804$1,104.17$11,205$505.18+$599.00ABIO
2$13,849$1,218.11$12,672$682.46+$1.2KABIO
3$16,154$1,335.59$14,490$930.48+$1.7KABIO
4$18,740$1,455.97$16,786$1,282.69+$2.0KABIO
5$21,631$1,578.61$19,753$1,791.56+$1.9KABIO
6$24,848$1,702.89$23,677$2,541.64+$1.2KABIO
7← crossover$28,415$1,828.18$29,008$3,672.99$593.00EPRT
8$32,358$1,953.89$36,463$5,425.08$4.1KEPRT
9$36,703$2,079.45$47,238$8,221.57$10.5KEPRT
10$41,476$2,204.34$63,385$12,840.73$21.9KEPRT

ABIO vs EPRT: Complete Analysis 2026

ABIOStock

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Full ABIO Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ABIO vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABIO vs SCHDABIO vs JEPIABIO vs OABIO vs KOABIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.